![Jim Banting](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jim Banting
Vorstandsvorsitzender bei
PARTEQ Innovations
Profil
Dr. Jim Banting is President & Chief Executive Officer at PARTEQ Innovations.
Prior to joining PARTEQ Innovations, Dr. Banting was employed as Head of Business Development by Sigma-Tau Pharmaceuticals, Inc., a U.S.
company focused on rare diseases.
Previously, he spent six years in the business development group of the U.S.
biotechnology company Human Genome Sciences.
In that role, he led the due diligence and negotiation of a number of in- and out-licensing, manufacturing, platform, and co-development related collaborations.
He has also worked at the proteomics company Caprion, securing numerous biomarker discovery collaborations with industry partners.
His career began as a co-founder of the Queen's spin-off company Vaxis Therapeutics that was funded by venture capitalists.
After growing the company, Dr. Banting served as the business development lead on the sale of Vaxis to a U.S.
specialty pharmaceutical company.
Dr. Banting graduated from Queen's in 1993 with an honours degree in Life Sciences.
He earned his doctorate in pharmacology at Queen's.
Aktive Positionen von Jim Banting
| Unternehmen | Position | Beginn |
|---|---|---|
PARTEQ Innovations
 PARTEQ Innovations Investment ManagersFinance PARTEQ Innovations makes equity and debt investments to commercialize technologies developed in their life and physical sciences programs. It provides financing for early stage capital requirement with an investments range from $50,000 to $150,000. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Jim Banting
| Unternehmen | Position | Ende |
|---|---|---|
Vaxis Therapeutics Corp
 Vaxis Therapeutics Corp Pharmaceuticals: MajorHealth Technology Manufactures and also researches pharmaceutical products | Corporate Officer/Principal | - |
Leadiant Biosciences, Inc.
 Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops novel medicines for rare diseases | Corporate Officer/Principal | - |
Human Genome Sciences, Inc.
 Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Provides pharmaceutical and diagnostic products | Corporate Officer/Principal | - |
Ausbildung von Jim Banting
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
99
Beziehungen ersten Grades
5
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Human Genome Sciences, Inc.
Human Genome Sciences, Inc. Medical SpecialtiesHealth Technology Provides pharmaceutical and diagnostic products | Health Technology |
Vaxis Therapeutics Corp
Vaxis Therapeutics Corp Pharmaceuticals: MajorHealth Technology Manufactures and also researches pharmaceutical products | Health Technology |
Queen's University
 Queen's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Leadiant Biosciences, Inc.
Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops novel medicines for rare diseases | Health Technology |
PARTEQ Innovations
PARTEQ Innovations Investment ManagersFinance PARTEQ Innovations makes equity and debt investments to commercialize technologies developed in their life and physical sciences programs. It provides financing for early stage capital requirement with an investments range from $50,000 to $150,000. | Finance |
